Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2025
Date Filed: March 27, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on operational milestones rather than financial performance data.
Material Changes
- Operational Milestone: Alterity Therapeutics Limited completed the last patient visit in its open-label trial.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the announcement of the trial milestone.
Investor Verification Checklist
- Verify the clinical outcomes and data release schedule following the completion of the open-label trial.
- Confirm the company's current cash runway and capital requirements given its development stage status.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on equity offerings and dilution.